The FDA issued Sydnexis with a complete response letter on 23 October, blocking SYD-101 from entering the US market.

This is an audio transcript of the Unhedged podcast episode: ‘Is Big Tech spending too much money?’ ...

An update from Ryanair Holdings ( (DE:RY4C) ) is now available.

Because AI training data is thin on Australian named entities, particularly indigenous place names like Wagga Wagga and ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Enphase Energy faces near-term headwinds, including weak Q3 2025 guidance and market share losses. Read why I rate ENPH stock ...

Q3 2025 net revenues increased 9.1% to $311 million , or 8.0% on a constant currency basis (1), compared to Q3 2024 Q3 2025 net income of $48 ...

After a week of intense policy meetings, the Federal Reserve, European Central Bank, and Bank of Japan have taken divergent ...

Things are better, but let’s not pop the champagne just yet.

Sydnexis, Inc., ( a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced topline results from the Phase 3 STAR trial of SYD-101, a proprietary 0.01% atropine ...

The Swiss Franc (CHF) declines further against the US Dollar (USD) on Tuesday, with USD/CHF extending gains for the fifth ...

Ovintiv Inc. (NYSE: OVV) (TSX: OVV) ("Ovintiv" or the "Company") today announced its third quarter 2025 financial and operating results. The Company plans to hold a conference call and webcast at 8:00 ...